LCMS-8080 triple quadrupole for LC/MS/MS analysis of complex matrices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

LCMS-8080 triple quadrupole for LC/MS/MS analysis of complex matrices

Shimadzu has introduced the LCMS-8080 triple quadrupole mass spectrometer which provides outstanding sensitivity with a large dynamic range and quantitation performance. The special design generates higher ion efficiency with further reduction of background noise, making the LCMS-8080 the preferred instrument for applications needing the highest level of sensitivity for analysis of complex matrices.

The system completes Shimadzu’s LCMS triple quadrupole family (LCMS-8030 and -8040) and enables customers to choose the best instrument solution for their demands with the smallest footprint on the market. Combined with the reliable and well-established Shimadzu HPLC / UFLC front end systems already known as the fastest systems with lowest carry-over market-wide, it is the perfect solution.

The excellent sensitivity is based on technologies such as Coaxial Hot gas providing efficient ionization, while HSID (Hot Source Induced Desolvation) removes neutral contaminants and ensures reliable introduction of the ions into the mass spectrometer. The Laminar Flow technology conveys large quantities of ions to the detector with high transmission efficiency at high speeds.

Detection limits are in the low femtogram range. The LCMS-8080’s sensitivity range is wider with higher accuracy quantitation than ever before achieved.

The LCMS triple quadrupole family is controlled by the well-known innovative and easy-to-use LabSolutions software. It provides seamless operation and a stress-free analysis environment. The refined Quantitation Browser which processes multiple analytes is a powerful function for quantitative analysis. The Data Browser enables users to analyze and compare multiple sets of data in the same window.

For more information please visit www.shimadzu.eu.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
FindPharma Custom Search

Click here